Navigation Links
Adamas Pharmaceuticals Announces Successful End-of-Phase 2 Meeting with FDA for Arimenda™
Date:5/15/2012

difficulty swallowing.  By providing a once-daily regimen for patients with moderate to severe Alzheimer's disease, Arimenda will meet the market need for a therapy that has the potential to ease caregiver burden, extend the duration of homecare, and delay the admission of patients to costly skilled nursing facilities.  Arimenda will be investigated in a Phase 3 safety study of up to 300 subjects to be conducted at approximately 50 centers in the United States and rest of the world. 

About Alzheimer's Disease

Alzheimer's disease is a chronic, progressive neurodegenerative condition that afflicts over 50 million patients worldwide including more than 5 million sufferers in the United States. The direct healthcare costs exceed $200 billion driven by moderate to severe patients who require care in nursing facilities and assisted living facility.  Caregiver burden is a second significant economic cost of the disease with 15 million caregivers providing 17 billion hours of unpaid care to dementia patients per year, valued at over $200 billion. The treated population is forecast to increase from the current 2.2 million to nearly 3.5 million by 2020.  

There is no cure on the horizon for Alzheimer's disease or for other diseases that cause dementia. Progression of dementia leads to dependence on caregivers and family, who struggle with managing activities of daily living, behavioral challenges, and complicated dosing regimens of the multiple medications that most dementia patients require. Recent outcome studies have shown that memantine and donepezil combination therapy, as compared to monotherapy, significantly increases the time nursing home admissions and significantly reduces health care costs. Despite these benefits, less than 30% of patients are currently treated with combination therapy. Adamas' Arimenda is specifically designed to address these issues, increasing the access to combination
'/>"/>

SOURCE Adamas Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Adamas Pharmaceuticals Signs CRADA With U.S. Navy to Conduct Preclinical Studies of Triple-Combination Antiviral Drug Therapy for Influenza A, Including the Novel H1N1 Pandemic Strain
2. In Vitro Study of Adamas Pharmaceuticals Triple Combination Antiviral Drug Therapy Shows Activity Against Drug-Resistant Influenza Viruses
3. Adamas Pharmaceuticals Announces In Vitro Data Demonstrating TCAD Therapy is More Potent Than Double Combinations or Monotherapy Against Drug-Resistant Flu Strains
4. Adamas Pharmaceuticals TCAD Therapy Demonstrates Broad Spectrum Activity Against Susceptible and Resistant Strains of Influenza in Animal Models
5. Adamas Pharmaceuticals Initiates a Phase 2/3 Clinical Study of ADS-5102 for Parkinsons Disease
6. Auxilium Pharmaceuticals, Inc. Receives Clearance to Resume Clinical Trials for XIAFLEX(TM)
7. Vion Pharmaceuticals Completes Accrual of 85 Patients to its Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) in Elderly AML
8. Solvay Pharmaceuticals, Inc. and Wyeth Pharmaceuticals Announce Receipt of an FDA Action Letter for Bifeprunox, an Investigational Treatment for Schizophrenia
9. Callisto Pharmaceuticals Opens Additional Sites for Phase II Clinical Trial of Atiprimod in Advanced Carcinoid Cancer Patients
10. WallSt.net (www.wallst.net) Updates the Investment Community Through an All-New Interview With RegeneRx Biopharmaceuticals CEO
11. Quark Pharmaceuticals, Inc. Presented Positive Preclinical Results of Systemic RNAi Compound for Acute Renal Failure (ARF)
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/28/2015)... FORT WORTH, Texas , May 28, 2015 /PRNewswire/ ... defines and segments the concerned market with analysis and ... million in 2014 and is estimated to reach $1,177.8 ... 2014 to 2019. Browse through the TOC ... the industry trends and segments, with help of various ...
(Date:5/28/2015)... Colo. , May 28, 2015  Array BioPharma ... encorafenib, binimetinib and selumetinib (licensed to AstraZeneca) at the ... which will be held May 29 – June 2, ... three products are currently advancing in a total of ... from both the NEMO (binimetinib monotherapy in NRAS mutant ...
(Date:5/28/2015)... , May 28, 2015  Pharmaceutic Labs announces ... under section 503B of the FDA,s Drug Quality ... the company is subject to Current Good Manufacturing ... medications according to the highest standards of CGMP ... 211. To continuously comply with FDA regulations and ...
Breaking Medicine Technology:Mannequin-Based Simulation Market Report is Expected to Reach $1,177.8 Million by 2019, at a CAGR of 19.4% from 2014 to 2019 2Mannequin-Based Simulation Market Report is Expected to Reach $1,177.8 Million by 2019, at a CAGR of 19.4% from 2014 to 2019 3Array BioPharma Announces Clinical Data Presentations At The 2015 ASCO Annual Meeting 2Array BioPharma Announces Clinical Data Presentations At The 2015 ASCO Annual Meeting 3
... LAS VEGAS, BASKING RIDGE, N.J., and TOTOWA, N.J., Jan. ... (CES), Verizon Wireless and VectraCor, Inc. today said the ... booth (Las Vegas Convention Center, South Hall, Booth #30259).  ... ambulatory cardiac monitor that incorporates an electrocardiogram (ECG) amplifier ...
... 10, 2012  Wells Pharmacy Network President, Robert L. ... opening of Wells Pharmacy,s corporate headquarters. Located in ... pharmacy is focused on serving the unique needs ... Compounding combines the art and skill of pharmacy with the ...
Cached Medicine Technology:Verizon Wireless' Network Supports VectraCor's Ambulatory Cardiac Monitor 2Verizon Wireless' Network Supports VectraCor's Ambulatory Cardiac Monitor 3"Wells Pharmacy Network" a Premier Compounding Pharmacy Focused on Serving the Unique Needs of the Medical and Veterinarian Communities Opens in Wellington 2
(Date:5/28/2015)... 28, 2015 New Jersey Plastic Surgeon ... delivering world-class results. With over 30 years of ... background in art, Dr. Rafizadeh knows what it takes ... to Plastic Surgery involves the principles of proportion, harmony ... superior level of comfort and personalized care from the ...
(Date:5/28/2015)... TN (PRWEB) May 28, 2015 Medelis, Inc., ... Taaffe has joined the company in the role of president. ... of leadership in the CRO industry,” said Larry Flanagan, Medelis’ ... guide the company through our next phase of growth.” ... oversaw its growth from nine employees to over 4,500 employees, ...
(Date:5/28/2015)... Boston Celtics Legend and Basketball Hall ... Foundation Board of Directors members, will be hosting their ... June 4-7. For the past 34 years, the Havlicek’s ... Foundation for children by bringing together friends, families, and ... John Havlicek Celebrity Fishing Tournament will be held from ...
(Date:5/28/2015)... Workers’ compensation costs per claim in Michigan were lower ... the Workers Compensation Research Institute (WCRI) said, with ... WCRI study, CompScope™ Benchmarks for Michigan, 15th Edition, ... more of work with those of 16 other states. ... 4 percent lower than similar claims from 2008. That was ...
(Date:5/28/2015)... Ticket Down is a reputable source of presale ... and Argentina in early September. , Two of the ... the pitch at AT&T Stadium in Arlington/Dallas, TX. Mexico and ... on Tuesday, September 8th at 9 p.m. The match will ... including some of the most loved players in the entire ...
Breaking Medicine News(10 mins):Health News:"NJ Top Doc", Dr. Farhad Rafizadeh is Excited to Offer New Services at his Plastic Surgery Practice 2Health News:"NJ Top Doc", Dr. Farhad Rafizadeh is Excited to Offer New Services at his Plastic Surgery Practice 3Health News:Bill Taaffe, Former President and CEO of ICON Clinical Research-US, Joins Medelis, a Specialty Oncology CRO, in the Role of President 2Health News:The Genesis Foundation Prepares for Their Final Annual John Havlicek Celebrity Fishing Tournament 2Health News:Michigan Workers’ Compensation Costs Lower Than Most States, Says WCRI Study 2Health News:Mexico vs. Argentina Tickets at AT&T Stadium: Ticket Down Slashes Ticket Prices on Argentina vs. Mexico Presale Tickets at AT&T Stadium for 9/8/15 Friendly Match 2Health News:Mexico vs. Argentina Tickets at AT&T Stadium: Ticket Down Slashes Ticket Prices on Argentina vs. Mexico Presale Tickets at AT&T Stadium for 9/8/15 Friendly Match 3
... Alan J. Zuccari,President & CEO of Hamilton Insurance Agency ... the American Health Care Association this,June for his recent ... be recognized by the AHCA," said Alan J. Zuccari. ... organization whose,ultimate focus is providing quality care.", Below ...
... the fact that the intestines have a separate immune ... the Kimmel Cancer Center at Jefferson in Philadelphia have ... of metastatic disease. , Reporting online Tuesday, June ... Cancer Institute , Scott Waldman, M.D., Ph.D., professor and ...
... Shield,of Illinois (BCBSIL) today donated $25,000 to the American ... the current floods, which,include northern Illinois, Iowa, and Missouri., ... people who have lost so much and,whose lives have ... said. "Nearly 1,200 Blue Cross employees live in or ...
... Karen Ignagni, President,and CEO of America,s Health ... response to the U.S. House of Representatives,passage of ... that would require Medicare,Advantage beneficiaries to pay for ... these cuts would have on vulnerable seniors.,As seniors ...
... metal devices, study suggests , , TUESDAY, June 24 (HealthDay ... better than those who received the bare-metal kind of ... a simple either-or issue, the study authors said. , ... recipients who underwent non-emergency stenting between October 2002 and ...
... of promising new anticancer agents could have unforeseen risks ... University School of Medicine in St. Louis. The anticancer ... hedgehog antagonists interfere with a biochemical process that ... showed that interfering with this biochemical process in mice ...
Cached Medicine News:Health News:Alan J. Zuccari Featured by the American Health Care Association as a June PAC Member 2Health News:Different type of colon cancer vaccine reduces disease spread, Jefferson scientists show 2Health News:Different type of colon cancer vaccine reduces disease spread, Jefferson scientists show 3Health News:Blue Cross and Blue Shield of Illinois Donates $25,000 to American Red Cross for Flood Disaster Recovery 2Health News:AHIP Statement on House Passage of H.R. 6331 2Health News:Drug-Coated Stents Reduce Repeat Artery Procedures 2Health News:Drug-Coated Stents Reduce Repeat Artery Procedures 3Health News:Certain anti-cancer agents could be harmful to patients with heart disease 2Health News:Certain anti-cancer agents could be harmful to patients with heart disease 3
... inverted microscope technology that offers you ... a microscope in this category. You will be ... 40 has been designed to make lab work ... increasing the efficiency of your workflow. Your advantage: ...
... The Eclipse TE2000S is an ... cell research. It's exclusive CFI60 ... with high numerical aperatures and ... first inverted microscope to take ...
... The IX71's modular frame ... 9 access ports for ... devices. Up to four ... access to a primary ...
... Designed to provide exceptional performance ... SteREO Lumar has unrivaled fluorescence ... light microscopy instruments. Developed for ... SteREO Lumar offers first-class optical ...
Medicine Products: